-DOCSTART- -X- O
MEDI-565 -X- _ B-Intervention
( -X- _ I-Intervention
also -X- _ I-Intervention
known -X- _ I-Intervention
as -X- _ I-Intervention
MT111 -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
a -X- _ O
bispecific -X- _ O
T-cell -X- _ O
engager -X- _ O
( -X- _ O
BiTE® -X- _ O
) -X- _ O
antibody -X- _ O
in -X- _ O
development -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
cancers -X- _ I-Patient
expressing -X- _ I-Patient
carcinoembryonic -X- _ I-Patient
antigen -X- _ I-Patient
( -X- _ I-Patient
CEA -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
MEDI-565 -X- _ B-Intervention
binds -X- _ O
CEA -X- _ B-Patient
on -X- _ I-Patient
cancer -X- _ I-Patient
cells -X- _ I-Patient
and -X- _ O
CD3 -X- _ O
on -X- _ O
T -X- _ O
cells -X- _ O
to -X- _ O
induce -X- _ O
T-cell -X- _ O
mediated -X- _ O
killing -X- _ O
of -X- _ O
cancer -X- _ O
cells. -X- _ O
To -X- _ O
understand -X- _ O
the -X- _ O
molecular -X- _ O
basis -X- _ O
of -X- _ O
human -X- _ O
CEA -X- _ B-Patient
recognition -X- _ O
by -X- _ O
MEDI-565 -X- _ B-Intervention
and -X- _ O
how -X- _ O
polymorphisms -X- _ O
and -X- _ O
spliced -X- _ O
forms -X- _ O
of -X- _ O
CEA -X- _ B-Patient
may -X- _ O
affect -X- _ O
MEDI-565 -X- _ B-Intervention
activity -X- _ O
, -X- _ O
we -X- _ O
mapped -X- _ O
the -X- _ O
epitope -X- _ O
of -X- _ O
MEDI-565 -X- _ B-Intervention
on -X- _ O
CEA -X- _ B-Patient
using -X- _ O
mutagenesis -X- _ O
and -X- _ O
homology -X- _ O
modeling -X- _ O
approaches. -X- _ O
We -X- _ O
found -X- _ O
that -X- _ O
MEDI-565 -X- _ B-Outcome
recognized -X- _ I-Outcome
a -X- _ I-Outcome
conformational -X- _ I-Outcome
epitope -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
A2 -X- _ I-Outcome
domain -X- _ I-Outcome
comprised -X- _ I-Outcome
of -X- _ I-Outcome
amino -X- _ I-Outcome
acids -X- _ I-Outcome
326–349 -X- _ I-Outcome
and -X- _ I-Outcome
388–410 -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
critical -X- _ I-Outcome
residues -X- _ I-Outcome
F -X- _ I-Outcome
( -X- _ I-Outcome
326 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
T -X- _ I-Outcome
( -X- _ I-Outcome
328 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
N -X- _ I-Outcome
( -X- _ I-Outcome
333 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
V -X- _ I-Outcome
( -X- _ I-Outcome
388 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
G -X- _ I-Outcome
( -X- _ I-Outcome
389 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
( -X- _ I-Outcome
390 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
E -X- _ I-Outcome
( -X- _ I-Outcome
392 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
I -X- _ I-Outcome
( -X- _ I-Outcome
408 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
N -X- _ I-Outcome
( -X- _ I-Outcome
410 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Two -X- _ I-Outcome
non-synonymous -X- _ I-Outcome
single-nucleotide -X- _ I-Outcome
polymorphisms -X- _ I-Outcome
( -X- _ I-Outcome
SNPs -X- _ I-Outcome
) -X- _ I-Outcome
( -X- _ I-Outcome
rs10407503 -X- _ I-Outcome
, -X- _ I-Outcome
rs7249230 -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
identified -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
epitope -X- _ I-Outcome
region -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
they -X- _ I-Outcome
are -X- _ I-Outcome
found -X- _ I-Outcome
at -X- _ I-Outcome
low -X- _ I-Outcome
homozygosity -X- _ I-Outcome
rates. -X- _ I-Outcome
Searching -X- _ O
the -X- _ O
National -X- _ O
Center -X- _ O
for -X- _ O
Biotechnology -X- _ O
Information -X- _ O
GenBank® -X- _ O
database -X- _ O
, -X- _ O
we -X- _ O
further -X- _ O
identified -X- _ O
a -X- _ B-Outcome
single -X- _ I-Outcome
, -X- _ I-Outcome
previously -X- _ I-Outcome
uncharacterized -X- _ I-Outcome
mRNA -X- _ I-Outcome
splice -X- _ I-Outcome
variant -X- _ I-Outcome
of -X- _ I-Outcome
CEA -X- _ I-Outcome
that -X- _ I-Outcome
lacks -X- _ I-Outcome
a -X- _ I-Outcome
portion -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
N-terminal -X- _ I-Outcome
domain -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
A1 -X- _ I-Outcome
and -X- _ I-Outcome
B1 -X- _ I-Outcome
domains -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
large -X- _ I-Outcome
portion -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
A2 -X- _ I-Outcome
domain. -X- _ I-Outcome
Real-time -X- _ I-Outcome
quantitative -X- _ I-Outcome
polymerase -X- _ I-Outcome
chain -X- _ I-Outcome
reaction -X- _ I-Outcome
analysis -X- _ I-Outcome
of -X- _ I-Outcome
multiple -X- _ I-Outcome
cancers -X- _ I-Outcome
showed -X- _ I-Outcome
widespread -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
full- -X- _ I-Outcome
length -X- _ I-Outcome
CEA -X- _ I-Outcome
in -X- _ I-Outcome
these -X- _ I-Outcome
tumors -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
less -X- _ I-Outcome
frequent -X- _ I-Outcome
but -X- _ I-Outcome
concordant -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
CEA -X- _ I-Outcome
splice -X- _ I-Outcome
variant. -X- _ I-Outcome
Because -X- _ O
the -X- _ O
epitope -X- _ O
was -X- _ O
largely -X- _ O
absent -X- _ O
from -X- _ O
the -X- _ O
CEA -X- _ O
splice -X- _ O
variant -X- _ O
, -X- _ O
MEDI-565 -X- _ B-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
bind -X- _ I-Outcome
or -X- _ I-Outcome
mediate -X- _ I-Outcome
T-cell -X- _ I-Outcome
killing -X- _ I-Outcome
of -X- _ I-Outcome
cells -X- _ I-Outcome
solely -X- _ I-Outcome
expressing -X- _ I-Outcome
this -X- _ I-Outcome
form -X- _ I-Outcome
of -X- _ I-Outcome
CEA. -X- _ I-Outcome
In -X- _ O
addition -X- _ O
, -X- _ O
the -X- _ B-Outcome
splice -X- _ I-Outcome
variant -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
interfere -X- _ I-Outcome
with -X- _ I-Outcome
MEDI-565 -X- _ I-Outcome
binding -X- _ I-Outcome
or -X- _ I-Outcome
activity -X- _ I-Outcome
when -X- _ I-Outcome
co-expressed -X- _ I-Outcome
with -X- _ I-Outcome
full-length -X- _ I-Outcome
CEA. -X- _ I-Outcome
Thus -X- _ O
MEDI-565 -X- _ B-Intervention
may -X- _ O
broadly -X- _ O
target -X- _ O
CEA-positive -X- _ B-Patient
tumors -X- _ I-Patient
without -X- _ O
regard -X- _ O
for -X- _ O
expression -X- _ O
of -X- _ O
the -X- _ O
short -X- _ O
splice -X- _ O
variant -X- _ O
of -X- _ O
CEA. -X- _ O
Together -X- _ O
our -X- _ O
data -X- _ O
suggest -X- _ O
that -X- _ O
MEDI-565 -X- _ B-Outcome
activity -X- _ I-Outcome
will -X- _ I-Outcome
neither -X- _ I-Outcome
be -X- _ I-Outcome
impacted -X- _ I-Outcome
by -X- _ I-Outcome
SNPs -X- _ I-Outcome
nor -X- _ I-Outcome
by -X- _ I-Outcome
a -X- _ I-Outcome
splice -X- _ I-Outcome
variant -X- _ I-Outcome
of -X- _ I-Outcome
CEA -X- _ I-Outcome
. -X- _ O

